Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases

PHASE3RecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

June 10, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2028

Conditions
Colorectal Cancer Liver MetastasesRegorafenib
Interventions
DRUG

Regorafenib and DIBIRI

"Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)~Drug: Irinotecan it will be mixed in eluting-beads and injected in the tumor.~Procedure: TACE Transcatheter arterial chemoembolization(TACE)is a minimally invasive procedure performed to decrease the tumor's blood supply.~Device: drug eluting-bead The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer."

DRUG

Regorafenib

Drug: Regorafenib Regorafenib will be given 3 weeks on/1 week off (initial dose: 80 mg od po.)

Trial Locations (1)

Unknown

RECRUITING

Bo Zhang, Guangdong

All Listed Sponsors
lead

Sun Yat-sen University

OTHER